 Kintara Therapeutics Inc has announced that the VAL-083 treatment arm in the Global Coalition for Adaptive Research GCAR registrational Phase 23 clinical trial for glioblastoma multiforme GBM has now been activated in 26 US sites as of August 16, 2021. The GBM AGILE Glioblastoma Adaptive Global Innovative Learning Environment trial is a patient-centered, adaptive platform trial for registration evaluating multiple therapies for patients with newly diagnosed and recurrent GBM. 